1-菲羧酸 | 27875-89-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 菲及其衍生物
• 中文名称: 1-菲羧酸
• 英文名称: 1-phenanthrenecarboxylic acid
• 英文别名: phenanthrene-1-carboxylic acid；Phenanthren-1-carbonsaeure；Phenanthrenecarboxylic acid；Phenanthren-carbonsaeure-(1)
• CAS: 27875-89-4
• 化学式: C₁₅H₁₀O₂
• 分子量: 222.243
• InChiKey: KFDKNTQGTAEZGC-UHFFFAOYSA-N

物化性质

• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2916399090

反应信息

• 作为反应物：
  描述：

  1-菲羧酸 在 lithium aluminium tetrahydride 、 氯化亚砜 作用下， 生成 1-氯甲基菲
  参考文献：
  名称：

  548.某些芳基甲基氯的溶剂分解速率，以及对该反应和类似反应的简单分子轨道处理

  摘要：

  DOI：

  10.1039/jr9560002789
• 作为产物：
  描述：

  phenanthrene-1-carbanilide 在 氢氧化钾 、 乙二醇 作用下， 生成 1-菲羧酸
  参考文献：
  名称：

  548.某些芳基甲基氯的溶剂分解速率，以及对该反应和类似反应的简单分子轨道处理

  摘要：

  DOI：

  10.1039/jr9560002789

文献信息

• Synthesis of 4-ketocyclopentene and cyclopentadiene compounds
  申请人：——

  公开号：US20020002308A1

  公开（公告）日：2002-01-03

  A process for forming 4-ketocyclopentene and substituted 4-ketocyclopentene compounds starting from the corresponding 1-carbohydrocarbyloxy-2-keto-4-hydroxy-5-cyclopentene by reduction followed by decarboxylation using zinc dichloride or zinc dibromide. The ketone may thereafter be converted to a cyclopentadiene compound by reducing the ketone to form an alcohol, replacing the hydroxyl functionality of the alcohol under substitution conditions with a leaving group, and deprotonating the resulting product under base induced elimination conditions to form the cyclopentadiene compound. Alternatively functionalized cyclopentadienyl compounds can be produced without isolation of an unsubstituted cyclopentadienyl compound by combining the elimination and deprotonation steps with a replacement step in a single unit operation.

  从相应的1-碳氢烷氧基-2-酮-4-羟基-5-环戊烯开始，通过还原后脱羧，使用氯化锌或溴化锌形成4-酮环戊烯和取代的4-酮环戊烯化合物的过程。然后，可以通过将酮还原形成醇，用取代条件下的离去基取代醇的羟基官能团，并在碱诱导的消除条件下去质子化所得产物以形成环戊二烯化合物。或者，可以通过将消除和去质子化步骤与替换步骤结合在单个单元操作中，而无需分离未取代的环戊二烯基化合物来生产功能化的环戊二烯基化合物。
• [EN] 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS<br/>[FR] COMPOSÉS 4-(4-PYRIMIDYL)-BENZAMIDES ET UTILISATION DE CEUX-CI COMME MODULATEURS DE L'ACTIVITÉ DE KINASES RHO (ROCK)
  申请人：ABBOTT GMBH & CO KG

  公开号：WO2009027392A1

  公开（公告）日：2009-03-05

  The present invention relates to novel 4-(4-pyridyl)-benzamides of the formula (I). The compounds I possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of Rho kinases (ROCKs). R1 and R2 are, independently of each other, hydrogen, hydroxy, cyano, C1-C8-alkyl, C1- C8-haloalkyl, C1-C8-alkoxy or C1-C8-haloalkoxy; R3, R4, R5 and R6 are, independently of each other, hydrogen, hydroxy, halogen, cyano, C1-C8-alkyl, C1-C8-haloalkyl, C1-C8-alkoxy, C1-C8-haloalkoxy, amino, C1-C8-alkylamino or di-(C1-C8-alkyl)-amino; R7 is hydrogen, C1-C8-alkyl, C1-C8-haloalkyl, aryl or aryl-C1-C8-alkyl; R8 is a group of the formula -X-W, where X is a single bond, C1-C4-alkylene or C1-C4-alkylene-O-, where the alkylene group in the three last-mentioned radicals may be linear or branched and may be partly or fully halogenated and/or may be substituted by a hydroxyl group and/or may be interrupted by an oxygen atom; and W is a cyclic radical selected from phenyl and a 5- or 6-membered saturated, partly unsaturated or aromatic heterocyclic ring which contains as ring members 1, 2 or 3 heteroatoms selected from O, S and N and optionally 1 or 2 carbonyl groups; R9 is a group of the formula -Y-Z, where Z is hydrogen, halogen, OR11, NR12R13, S(O)m-R14, phenyl which may carry 1, 2, 3 or 4 substituents R15 or a 5- or 6-membered saturated, partly unsaturated or aromatic heterocyclic ring; and Y is linear or branched C1C4-alkylene which may be partly or fully halogenated and/or may be substituted by a hydroxyl group and/or a phenyl ring; or, in case Z is phenyl or the 5- or 6-membered heterocyclic ring as defined above, Y can also be a single bond.

  本发明涉及公式（I）的新型4-(4-吡啶基)-苯甲酰胺。化合物I具有有价值的治疗性能，并且特别适用于治疗对Rho激酶（ROCKs）调节产生反应的疾病。R1和R2分别为氢、羟基、氰基、C1-C8-烷基、C1-C8-卤代烷基、C1-C8-烷氧基或C1-C8-卤代烷氧基；R3、R4、R5和R6分别为氢、羟基、卤素、氰基、C1-C8-烷基、C1-C8-卤代烷基、C1-C8-烷氧基、C1-C8-卤代烷氧基、氨基、C1-C8-烷基氨基或二(C1-C8-烷基)-氨基；R7为氢、C1-C8-烷基、C1-C8-卤代烷基、芳基或芳基-C1-C8-烷基；R8为-X-W的基团，其中X为单键、C1-C4-烷基或C1-C4-烷基-O-，在上述最后三个基团中的烷基可以是直链或支链，可以部分或完全卤代，和/或可以被羟基取代，和/或可以被氧原子打断；W为选择自苯基和含有1、2或3个来自O、S和N的杂原子以及可选地包含1或2个羰基的5-或6-成员饱和、部分不饱和或芳香杂环的环基；R9为-Y-Z的基团，其中Z为氢、卤素、OR11、NR12R13、S(O)m-R14、可能携带1、2、3或4个取代基R15的苯基或5-或6-成员饱和、部分不饱和或芳香杂环的环基；Y为线性或支链的C1-C4-烷基，可以部分或完全卤代，和/或可以被羟基取代，和/或可以是苯环；或者，如果Z为苯基或上述定义的5-或6-成员杂环环，Y也可以是单键。
• [EN] SILYL ALKYL ESTERS OF ANTHRACENE- AND PHENANTHRENE CARBOXYLIC ACIDS<br/>[FR] ESTERS ALKYLIQUES SILYLES D'ACIDES ANTHRACENE ET PHENANTHRENE-CARBOXYLIQUES
  申请人：HONEYWELL SPECIALTY CHEMICALS

  公开号：WO2004000853A1

  公开（公告）日：2003-12-31

  The invention relates to silyl alkyl esters, in particular of anthracene and phenanthrene carboxylic acids, a process for their preparation, compositions and polysiloxane compositions which contain the silyl alkyl esters and which can be used in particular in the semiconductor industry for the preparation of anti-reflective layers for photolithographic applications.

  本发明涉及硅烷基烷基酯，特别是蒽酸和菲酸的酯，其制备方法，以及含有硅烷基烷基酯的组合物和聚硅氧烷组合物。这些组合物可以用于半导体工业中的光刻应用中，用于制备抗反射层。
• 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors
  申请人：Chau Anh

  公开号：US20090075998A1

  公开（公告）日：2009-03-19

  The invention encompasses novel compounds of Formula I or pharmaceutically acceptable salts thereof. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful to treat pain and/or inflammation from a variety of diseases or conditions, such as osteoarthritis, rheumatoid arthritis and acute or chronic pain. Methods of treating diseases or conditions mediated by the mPGES-1 enzyme and pharmaceutical compositions are also encompassed.

  该发明涵盖了式I的新化合物或其药学上可接受的盐。这些化合物是微粒体前列腺素E合酶-1（mPGES-1）酶的抑制剂，因此可用于治疗多种疾病或情况引起的疼痛和/或炎症，如骨关节炎，类风湿性关节炎和急性或慢性疼痛。还包括治疗由mPGES-1酶介导的疾病或情况的方法和制药组合物。
• 2-(Phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors
  申请人：Chau Anh

  公开号：US20070208017A1

  公开（公告）日：2007-09-06

  The invention encompasses novel compounds of Formula I or pharmaceutically acceptable salts thereof. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful to treat pain and/or inflammation from a variety of diseases or conditions, such as osteoarthritis, rheumatoid arthritis and acute or chronic pain. Methods of treating diseases or conditions mediated by the mPGES-1 enzyme and pharmaceutical compositions are also encompassed.

  本发明涵盖了公式I的新化合物或其药学上可接受的盐。这些化合物是微粒体前列腺素E合成酶-1（mPGES-1）酶的抑制剂，因此可用于治疗各种疾病或病况引起的疼痛和/或炎症，如骨关节炎、类风湿性关节炎和急性或慢性疼痛。还包括治疗由mPGES-1酶介导的疾病或病况的方法和制药组合物。